Additionally, futibatinib, a selective and irreversible inhibitor of FGFR1/2/3/4, significantly improved clinical outcomes in advanced iCCA patients with FGFR2 gene fusion-rearrangement in a phase II study, following one or more prior lines of systemic therapy [82]. The gene discussed is FGFR2; the disease is infantile convulsions and choreoathetosis.